Alnylam Pharmaceuticals, Inc. (ALNY)

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

As of November 3, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) stock rose to $160.41, up 1.53% (+$2.41) versus the previous close. On the day, shares have traded between $156.72 and $161.58. That puts ALNY near the bottom of its 52-week range of $156.00 to $479.79. Alnylam Pharmaceuticals, Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $22.10 billion, with about 1.66 million shares changing hands.

Latest ALNY news

• Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026Yahoo Finance· Nov 3, 8:30 AM ETAHAISA
• Oracle upgraded, Reddit downgraded: Wall Street's top analyst callsYahoo Finance· Nov 2, 9:55 AM ET
• Should You Buy The Dip In Alnylam Stock?trefis.com· Nov 2, 9:39 AM ET
• Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resiliencebiopharmadive.com· Nov 2, 9:00 AM ET
• Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More247wallst.com· Nov 2, 8:13 AM ET
• FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlightstocktwits.com· Nov 2, 5:36 AM ET
• 5 Best High Growth Stocks Outside Big TechYahoo Finance· Oct 31, 5:39 PM ET
• Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales ConcernsYahoo Finance· Oct 31, 12:21 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want ALNY headlines, alerts and AI research in one place? Create a free account →

• $ALNY @Pika_Capital is this one worth a consideration?

  @RookyMoves· Nov 3, 11:29 AM ET

• $ALNY 3.8x 26' Revenue. Market, are you okay?

  @AsymmetricUpsideEnjoyer· Nov 3, 11:28 AM ET

• $ALNY shitty management. FDA is in November. Alny will receive a payout and sales % if approved

  @Olena· Nov 3, 11:02 AM ET

• $ALNY Barclays maintains Alnylam Pharmaceuticals at Overweight, set price target to $380 🫠🫠🫠

  @sampeper· Nov 3, 10:51 AM ET· Bullish

• $ALNY breaking news: Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026 https://www.businesswire.com/news/home/20261103351345/en/Alnylam-to-Present-Five-Year-HELIOS-B-D…

  @sampeper· Nov 3, 10:50 AM ET· Bullish

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →